Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up

NCT01471821 is registered in ClinicalTrials.gov with Juan A. Arnaiz as lead sponsor.

NCT NCT01471821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01471821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up
Lead sponsor
Juan A. Arnaiz
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2011
Completion date
April 30, 2014
Enrollment
250 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection